MSH6
- Known as:
- MSH6
- Catalog number:
- DM429
- Product Quantity:
- 1 ml
- Category:
- -
- Supplier:
- ACR
- Gene target:
- MSH6
Related genes to: MSH6
- Gene:
- MSH6 NIH gene
- Name:
- mutS homolog 6
- Previous symbol:
- GTBP
- Synonyms:
- -
- Chromosome:
- 2p16.3
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-29
- Date modifiied:
- 2019-04-23
Related products to: MSH6
Related articles to: MSH6
- Synchronous colorectal cancers (SCRCs) with discordant mismatch repair (MMR) status present unique clinical and therapeutic challenges. This case report describes a rare instance of synchronous ascending colon and rectal adenocarcinomas arising from distinct tumorigenic pathways (Lynch-like syndrome and serrated pathway). We aim to explore the mechanism underlying MMR status heterogeneity, and emphasize the clinical value of lesion-specific molecular profiling combined with regional metastatic lymph node MMR phenotyping for individualized treatment of this condition. - Source: PubMed
Publication date: 2026/04/27
Chen DamingZhang JianshengBi JinchaoBai ZhiyueZhang LeiBai Jingzhen - Chromosome 2p21 harbors , a major driver gene for holoprosencephaly (HPE). Large copy number variants (CNVs) overlapping 2p21p16.2 are rare and may present with pleiotropic congenital anomalies. - Source: PubMed
Publication date: 2026/03/11
Keçeci RamazanKeçeci Hayriye NerminBüyükeren MelekYılmaz Fatma HilalÖzcan Beyza - A subset of triple negative breast cancer (TNBC) patients shows resistance to standard neoadjuvant chemotherapy (NAC), resulting in high relapse and mortality risk. This highlights the need for predictive biomarkers and alternative treatment strategies. Targeted molecular profiling was performed on post-NAC resection specimens from 138 TNBC patients, diagnosed across multiple centers between 2013 and 2022, all exhibiting extensive poor response, defined as >50% residual tumor and the development of distant metastasis. Integrated immunohistochemistry and genomic analyses were conducted to identify potentially targetable alterations. Most post-NAC TNBCs (60%) were HER2-ultralow or HER2-low. Among 85 patients with successful DNA sequencing, 2640 variants were detected, with TP53 mutations being most frequent (94%). Mutation count ranged from 3 to 1668 per patient (median n = 11). Several altered genes, including ERBB2, BRCA1/2, PIK3CA, and RB1, have been associated with favorable responses to targeted therapeutics in clinical trials. Moreover, 208 potential neo-peptide targets (median per patient n = 3) were detected across recurrently mutated genes such as ATM, CREBBP, IRS2, KEAP1, MSH6, NOTCH1, NOTCH2, POLD1, TP53, and TSC2. Molecular profiling of residual disease in extensively poor responding TNBC post-NAC revealed multiple potentially targetable variant, supporting the use of next-generation sequencing to guide personalized strategies for these high-risk TNBC patients. - Source: PubMed
Publication date: 2026/05/13
van den Ende Nadine SSmid MarcelMartens John W MDebets RenoJager Agnesvan Deurzen Carolien H M - Many breast cancer predisposition genes are involved in DNA damage repair, leading to genome instability that can impact immunosurveillance, neoantigen formation, and the composition of the tumor immune microenvironment. - Source: PubMed
Publication date: 2026/05/09
Rojas-Rodríguez FelipeCanisius SanderKeeman RenskeBernstein Aaron JHurson Amber NAhearn Thomas UAndrulis Irene LAntoniou Antonis CBehrens SabineBiałkowska KatarzynaBlows Fiona MBolla Manjeet KCamp Nicola JCessna Melissa HChang-Claude JennyChanock Stephen JDennis JoeDevilee PeterDunning Alison MGronwald JacekHamann UteHollestelle AntoinetteHooning Maartje JHorlings Hugo MJager AgnesJakubowska AnnaJones BrandtKaaks RudolfKok MarleenLissowska JolantaLubiński JanManoochehri MehdiMiller Jodi LMuhammad NoorMulligan Anna MarieObi NadiaRashid Muhammad USinn Hans-Petervan Deurzen Carolien H MWang QinWilliams Justin AYang Xiaohong REaston Douglas FAli H RazaGarcía-Closas MontserratPharoah Paul D PAbubakar MustaphaSchmidt Marjanka K - To explore uptake of risk-reducing gynecologic surgery in a diverse patient population with Lynch syndrome. - Source: PubMed
Publication date: 2026/05/07
Waggoner Rebecca MRicker Charité NNie QiGuo X MonaComeaux Jacob GChang Emmeline YGutierrez NataliaHernandez DaisyNguyen AveriGarcia IvanIto FumitoBrunette Laurie LRoman Lynda DSpicer DarcyCulver Julie O